seviprotimut-L (Polynoma Melanoma Vaccine)

About TransCode Therapeutics

TransCode Therapeutics is a Boston-based biotech founded in 2016 with a mission to develop novel therapeutics for metastatic cancer, a historically underserved area of oncology. Its core achievement is the TTX platform, an iron oxide nanoparticle system designed to solve the persistent delivery challenge for oligonucleotides, enabling its lead candidate TTX-MC138 to target a key metastatic driver. The company's strategy involves advancing its RNA pipeline while leveraging the late-stage clinical assets from its acquisition of Polynoma LLC to create nearer-term value inflection points. As a public company, TransCode is in a capital-intensive clinical development stage, aiming to address a significant unmet medical need across multiple solid tumors.

Therapeutic Areas